Expensive and softening.

Trading above fair value while the fundamentals weaken — little to like right now.

Price $28.89 taken 2026-11-15 · market cap about $165B
Fair value $21 range $14 to $33 · from the FY25 annual report
Margin of safety −26%, above fair value no margin of safety · the price sits above fair value

The five checks

1 caution · 4 warning

  • Warning
    Overvalued
    Fair value ~$21 vs $29 — trading 26% above what the math supports.
  • Warning
    Price assumes a big acceleration
    You'd need ~8%/yr free-cash-flow growth to justify today's price; it has done -29.6%/yr lately.
  • Warning
    Revenue shrinking
    Down 1.6% last year — cheap may mean broken.
  • Caution
    Cash flow flat-to-down
    Free cash flow ~-29.6%/yr — big, but not compounding. The crux for a value buyer.
  • Warning
    Heavy debt load
    Net debt of $51B — roughly 6× annual free cash flow. This changes the risk picture.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $29 to make sense?

The price needs ~8% a year
Pfizer has delivered -29.6% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, FY25Operating cash flow less capital spending, from the annual report$9B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$74B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $99B
  4. The business, in today's money$173B
  5. Subtract net debtBorrowings and finance leases less cash and securities− $51B
  6. Divide by the shares on file÷ 5.713B

Fair value per share$21

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $14 to $33 range comes from.

3% growth5% growth7% growth
8% discount$22$27$33
9% discount$17$21$26
10% discount$14$17$21

The blue cell is the published method. Some cells sit above today’s price, some below.

Free cash flow, ten years

$ billions · Form 10-K

$14B FY16 $15B FY17 $14B FY18 $11B FY19 $12B FY20 $30B FY21 $26B FY22 $4.8B FY23 $9.8B FY24 $9.1B FY25
  1. FY25 $9.1B
  2. FY24 $9.8B
  3. FY23 $4.8B
  4. FY22 $26B
  5. FY21 $30B
  6. FY20 $12B
  7. FY19 $11B
  8. FY18 $14B
  9. FY17 $15B
  10. FY16 $14B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Pfizer Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Pfizer that is about $51B, or $9 per share. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $28.89 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Pfizer another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →